Genscript Biotech (01548) Surges Nearly 9% in Early Trading as CARVYKTI Third-Quarter Sales Reach $710 Million with Continued Sequential Growth

Genscript Biotech (01548) rose nearly 9% in early trading. As of press time, the stock was up 7.18% at HK$35.82, with a turnover of HK$386 million.

On the news front, Genscript Biotech recently announced that Legend Biotech disclosed that CARVYKTI's net trade sales for the third quarter of 2026 were approximately $710 million. Combined with first-half revenue of $1.254 billion, Carvykti's cumulative sales for the first three quarters reached approximately $1.964 billion, representing a year-on-year increase of 47.4%. In terms of quarterly trends, the product recorded sales of $597 million in Q1, $657 million in Q2, and further climbed to $710 million in Q3, showing continuous sequential volume growth.

It is worth noting that on September 16, Genscript Biotech announced a collaboration with Eli Lilly's AIDD platform Lilly TuneLab. Under the agreement, the company will provide wet lab services to TuneLab participating companies, helping them rapidly generate experimental data, convert AI predictions into biological validation data, and accelerate candidate drug evaluation. JPMorgan stated that this move represents a strategic entry point to access an ecosystem of over 100 biotech clients and to close the loop between dry and wet lab experiments.